Nafarelin
As of the edition of 20 October 2026, Nafarelin is a protein: marketed, first approved in 1990 (US); acts on GNRHR; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Protein
- Brand name
- Synarel
- First approved
- 13 February 1990 (US)
- Approvals on record
- 6 in 5 regions
- Holder of the most recent approval
- Pfizer
- Registered trials
- 5, 1 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Nafarelin.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | P30968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 2 | 2 | 1 | 0 | 1 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Acquired holder | 2020 to now |